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The high morbidity and mortality rates of COVID-19 have led many countries to impose a 
lockdown as an extreme measure to prevent contagion. Accordingly, concerns were raised 
about worsening of Parkinson’s disease (PD) patients’ symptoms1-3, as well as for their 
caregivers’ mental health. We hypothesized that different PD features may impact on 
patients’ and caregivers’ stress under lockdown. To this aim, we prospectively carried out a 
series of structured telephone interviews to each pair (PD/caregivers), conducted by the 
treating neurologist during the last 10 days of lockdown in Italy. The study was approved by 
the ethical committee of Brotzu General Hospital (PG/2020/11022). Patient and caregivers 
provided written consent by email.  
Inclusion criteria were diagnosis of PD according to MDS clinical criteria4 and having a family 
member as caregiver. Change of stress level of PD and caregivers was compared to the 
time prior to home confinement and assessed with a self-reported judgement (verbal rating 
scale, VRS). Answers were transposed on a scale from 0 (severely worsened) to 6 (much 
improved), where 3 stood for unchanged. VRS for each item were categorized in worsened 
(score 0-2) and unchanged/improved (score 3-6). The following clinical variables were 
assessed in PD: Unified Parkinson’s Disease Rating Scale part II (UPDRS-II), Non-Motor 
Symptoms Scale (NMSS), Questionnaire for Impulsive-Compulsive Disorders in Parkinson's 
Disease–Rating Scale, Parkinson’s disease questionnaire-8. Hospital Anxiety and 
Depression Scale (HADS) were retrieved in PD and caregivers, who also underwent Zarit 
burden interview (ZBI). PD patients were also categorized in two groups based on whether 
or not they continued to practice at least 45’ per day of physical activity during the home 
confinement. Full methods, including statistical analysis, are in supplementary material. 
We enrolled 32 PD and 32 caregivers (supplementary table 1). Level of stress during home 
confinement was rated as worsened in 43.8% of PD and 53.1% of caregivers. PD 
experiencing increased stress level had worse HADS-anxiety (p=0.006) and NMSS 
(p=0.012). In PD the increase in stress due to NMSS was driven by mood/cognition score. 
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Patients’ features associated to higher level of stress in caregivers were worse NMSS 
(p=0.018). Specifically, cardiovascular, mood/cognition, urinary and miscellaneous domain 
of NMSS scored higher in PD patients whose caregivers had worsened stress (Figure 1). 
On multivariate binary logistic regression, worsening stress were associated to patients’ 
HADS-anxiety (p=0.032) in PD and NMSS (p=0.018) in caregivers. Similarly, on multivariate 
linear regression analysis a higher ZBI was associated with a higher NMSS (p=0.029) 
(supplementary table 2). PD practicing daily physical activity had lower anxiety compared 
with those who were inactive (6.0 ±3. vs 8-7 ±3, p=0.044). The two groups were similar for 
other clinical and demographic features. Multivariate linear regression showed a significant 
association between HADS-anxiety in PD and lack of physical activity during home 
confinement, even when controlling for age, disease duration, total Levodopa equivalent 
daily dose, UPDRS-II, NMSS and QUIP-RS (supplementary tables 3 and 4). 
The binary and multiple regression models adequately fitted the data. There was no 
evidence of collinearity between NMSS and UPDRS-II (supplementary material). 
NMS particularly neuropsychiatric5 and sleep disturbances6, are known predictors of 
caregiver burden. COVID-19 related confinement period resulted in an additional load of 
pressure on the caregiver, especially caused by NMSS belonging to the neuropsychiatric 
and autonomic domain. Differently, only anxiety was a significant determinant of worsening 
stress in PD patients, as recently reported2. Limitations of our study are the small sample 
size and the use of telephone interviews.
Despite the small sample size and the use of a non-validated outcome measure such as 
VRS, we believe these findings should be taken into account in the post-pandemic time. The 
maintenance of a minimum level of physical activity should represent an essential non-
pharmacological measure also for the management of PD anxiety. Moreover, our study 
highlights that, under strict home confinement, different PD symptoms has a distinct but 
significant impact not only on patients’ but also on caregivers’ stress. Post-pandemic health 
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care systems should take care of such unpaid compassionate group that bears a huge and 
growing burden on society.
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Figure 1. Panels A-C: Parkinson’s disease (PD) experiencing increased stress level during 
lockdown had worse NMSS (*p=0.012) and HADS-anxiety (*p=0.006). Patients’ features 
associated to higher level of stress in caregivers (CVG) were worse NMSS (*p=0.018). 
UPDRS-II was not associated to higher stress level in both PD and caregivers. Panel D: 
Cardiovascular, mood/cognition, urinary and miscellaneous domain of NMSS scored higher 
in caregivers with worsened stress. Panel E: In PD, increased stress by NMSS was driven 
by mood/cognition score.
Supplemental Material. 
This file includes additional details about the methods, analysis, and results related to this 
paper. Four Supplemental Tables are also provided
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Panels A-C: Parkinson’s disease (PD) experiencing increased stress level during lockdown had worse NMSS 
(*p=0.012) and HADS-anxiety (*p=0.006). Patients’ features associated to higher level of stress in 
caregivers (CVG) were worse NMSS (*p=0.018). UPDRS-II was not associated to higher stress level in both 
PD and caregivers. 
Panel D: Cardiovascular, mood/cognition, urinary and miscellaneous domain of NMSS scored higher in 
caregivers with worsened stress. 
Panel E: In PD, increased stress by NMSS was driven by mood/cognition score. 
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SUPPLEMENTARY METHODS
The telephone interview included two distinct sections, designed to separately 
assessing PD and caregivers. For those patients having problems in completing the 
interview themselves, (e.g. due to dysarthria, hypophonia or cognitive impairment), 
this was conducted with the help of caregivers. The interview had a duration of 
approximately 50 minutes.
STATISTICAL ANALYSIS
Pearson Test was used to run correlation between continuous variables. Spearman 
test was used to evaluate correlation between non-parametric variables. Unpaired t-
test for independent sample was employed to compare means of non-parametric 
continuous variables. 
Linear Regression analysis was used to evaluate relationship between ZARIT total 
score (dependent variable) and motor score UPDRS II total and NMSS (independent 
variable).  Linear regression analysis was also employed to assess the association 
between HAM-A (dependent variable) and the following independent variables: 
physical activity (Yes/No), age (years), disease duration (years), Total Levodopa 
Equivalent Daily Dose (LEDD) (mg), UPDRS II, NMSS, PDQ8, QUIP-RS.
Binary Logistic regression was used to evaluate the relationship between presence of 
a worsened VRS (dependent variable) and UPDRS II total score and NMSS 
(independent variable). Results were considered significant when P ≤ 0.05. 
Analyses were performed using SPSS 20.0 for Mac.
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SUPPLEMENTARY RESULTS
We evaluated the fit of the model for the binary logistic regression reported in 
supplementary table 2 with Hosmer-Lemeshow test. This test indicates a poor fit if the 
significance value is l< 0.05. We found a p-value, respectively, of 0.32 (for the 
dependent variable worsened VRS for patient’s stress) and of 0.62 (for dependent 
variable worsened VRS for caregiver’s stress), indicating that the model adequately 
fits these data. 
The fit of the model for the reported linear regressions was evaluated by ANOVA test. 
For linear regression with dependent variable ZBI, the R Square was 0.38 (p=0.001). 
For linear regression with dependent variable HADS, the R Square was 0.48 (p=0.03). 
These results support the hypothesis that the model adequately fits the data.
We also tested collinearity between UPDRS-II and NMSS. Lack of collinearity was 
confirmed by the correlation test between NMSS and UPDRS II, which showed 
statistically significant correlation values (rho = 0.72) but lower than those generally 
indicative of collinearity (i.e. rho= 0.8-0.9) (H. Mayers. Classical and Modern 
Regression with Applications. PWS10 Kent Publishing Company. 1990).  
Moreover, we performed a collinearity diagnostic test regarding the linear regression 
reported in supplementary table 2 (dependent variable: ZBI score. Independent 
variable: NMSS. UPDRS II). The variance inflation factor (VIF) values (1.9) and the 
condition index results (1.0, 4.2 and 6.9) were not indicative of collinearity. 
Finally, statistical analysis performed on supplementary table 4 variables did not 
support the possibility of collinearity between the variables, showing VIF value 
between 1.1 and 4.1.
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SUPPLEMENTARY TABLE 1. 
DEMOGRAPHICAL AND CLINICAL FEATURES OF PATIENTS WITH PARKINSON’S DISEASE (PD) AND 
THEIR CAREGIVERS 
D-Ag= dopamine agonist; HADS = Hospital Anxiety and Depression Scale; LEDD = levodopa equivalent daily 
dose; NMSS = Non-Motor Symptoms Scale; PDQ-8; Parkinson’s disease questionnaire-8 ; QUIP-RS = 
Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease–Rating Scale; UPDRS = Unified 
Parkinson’s Disease Rating Scale.
All continuous data given as mean ± standard deviation. * Significant values are bolded.
 PD (N=32) Caregivers (N=32) p-value
M/F (%) 24/8 (75) 6/26 (18.8) <0.0001*
Age, years 72.5 ± 8.7 64.63 ± 10.32 0.024*
Education, years 11.38 ± 5.24 12.78 ± 5.31 0.236
HADS Anxiety 6.78 ± 3.34 6.78 ± 4.52 0.808
HADS Depression 7.72 ± 4.18 5.97 ± 3.93 0.126
Lockdown Stress (worsened 
/unchanged or improved) (%) 14/18 (43.8) 17/15 (53.1) 0.617
Age at onset, years 60.58 ± 10.53 -
Disease duration, years 11.62 ± 4.51 -
Total LEDD, mg 959.31 ± 344.95 -
D-ag LEDD, mg 135.41 ± 162.69 -
UPDRS-II 18.44 ± 8.33 -
Schwab and England 62.19 ± 17.54 -
NMSS 73.56 ± 47.04 -
QUIP-RS 4.84 ± 4.62
PDQ8 12.63 ± 6.42 -
ZARIT BURDEN INTERVIEW - 18.16 ± 17.07
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SUPPLEMENTARY TABLE 2. 
BINARY LOGISTIC REGRESSION AND LINEAR REGRESSION ANALYSES ON FACTORS ASSOCIATED TO 
WORSENING OF STRESS AND CAREGIVER BURDEN DURING LOCKDOWN DUE TO COVID-19.
BINARY LOGISTIC REGRESSION ANALYSIS - Dependent variable VRS for stress worsening
B Exp(B) P-value 95% CI - LB 95% CI - UB
NMSS -0.011 0.989 0.380 0.964 1.014
UPDRS II -0.008 0.992 0.904 0.865 1.137PD
HADS-A -0.365 0.694 0.032* 0.497 0.970
NMSS -0.048 0.953 0.018* 0.916 0.992CAREGIVER
UPDRS II 0.124 1.132 0.136 0.962 1.333
LINEAR REGRESSION ANALYSIS - Dependent variable ZBI
UC SC
B SE Beta t P-value 95% CI - LB 95% CI - UB
UPDRS II 0.399 0.414 0.195 0.963 0.344 -0.449 1.246
NMSS 0.169 0.073 0.464 2.294 0.029* 0.018 0.319
CI= confidence interval; HADS-A: Hospital Anxiety and Depression scale, Anxiety score; LB= lower bound; 
NMSS = Non-Motor Symptoms Scale; UB= upper bound; SC= Standardized Coefficients; UC = 
Unstandardized Coefficients; UPDRS = Unified Parkinson’s Disease Rating Scale; ZBI = Zarit Burden Interview. 
* Significant values are bolded.
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SUPPLEMENTARY TABLE 3. 
DEMOGRAPHICAL AND CLINICAL FEATURES OF PARKINSON’S DISEASE (PD) CATEGORIZED ON 
PRACTIZING HOME PHYSICAL ACTIVITY
HADS = Hospital Anxiety and Depression Scale; LEDD = levodopa equivalent daily dose; NMSS = Non-
Motor Symptoms Scale; PDQ-8; Parkinson’s disease questionnaire-8 ; QUIP-RS = Questionnaire for 
Impulsive-Compulsive Disorders in Parkinson’s Disease–Rating Scale; UPDRS = Unified Parkinson’s 
Disease Rating Scale.






Age, years 73.4 ± 8 70.1 ±11 0.342
Disease duration, 
years
11.9 ± 4 10.9 ± 6 0.572
Total LEDD, mg 905 ± 303 1096 ±424 0.163
UPDRS II 17.5 ± 8 20.9 ± 10 0.306
Schwab & England 63.0 ± 17 60.0 ± 20 0.666
NMSS 73.2 ± 50 74.6 ± 42 0.942
HADS-A 6.0 ± 3 8.7 ± 3 0.044
HADS-D 8.0 ± 5 7.0 ± 3 0.552
PDQ-8 12.4 ± 7 13.2 ± 6 0.748
QUIP-RS 4.7 ± 5 5.1 ± 5 0.842
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SUPPLEMENTARY TABLE 4. 
LINEAR REGRESSION ANALYSIS OF VARIABLES ASSOCIATED TO ANXIETY IN PD UNDER LOCKDOWN
CI= confidence interval; HADS-A: Hospital Anxiety and Depression scale, Anxiety score; LB= lower 
bound; NMSS = Non-Motor Symptoms Scale; UB= upper bound; SC= Standardized Coefficients; UC = 
Unstandardized Coefficients; UPDRS = Unified Parkinson’s Disease Rating Scale; 
* Significant values are bolded.
LINEAR REGRESSION ANALYSIS - Dependent variable HADS-ANXIETY
UC SC
B SE Beta t P-value
95% CI - 
LB




-2.932 1.320 -0.404 -2.222 0.037 -5.669 -0.195
Age (years) 0.046 0.087 0.122 0.531 0.600 -0.134 0.226
Disease 
duration (years)
-0.094 0.174 -0.127 -0.541 0.594 -0.455 0.267
Total LEDD (mg) -0.001 0.003 -0.079 -0.278 0.784 -0.006 0.005
UPDRS II -0.049 0.102 -0.125 -0.484 0.633 -0.261 0.162
NMSS 0.000 0.022 0.004 0.013 0.989 -0.044 0.045
PDQ8 0.241 0.161 0.470 1.500 0.148 -0.092 0.575
QUIP-RS 0.234 0.121 0.322 1.928 0.067 -0.018 0.485
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